Amplia Therapeutics Achieves Landmark Patent Grant
Highlights
Amplia Therapeutics Limited has secured a vital patent for the FAK inhibitor, narmafotinib, from the US Patent and Trademark Office.
This patent ensures that narmafotinib will be protected until at least 2040.
Recently, Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) announced an exciting development in its journey. The company has officially received a Certificate of Grant from the US Patent and Trademark Office for a key patent titled A salt and crystal form of a FAK Inhibitor. This pivotal patent follows an earlier notification of allowance from the USPTO.
The patent specifically shields the unique form of narmafotinib that Amplia is advancing in clinical trials. This protection is crucial as it extends the company's intellectual property rights not only in the U.S. but also across multiple significant jurisdictions, such as Europe, Japan, India, South Korea, and Australia, where the patent has already been granted. This longevity of protection extends to a minimum of 2040, safeguarding Amplia's investments and efforts in this developing area.
Amplia's Vision for Narmafotinib
Dr. Chris Burns, CEO of Amplia, expressed enthusiasm regarding this milestone, stating, "With the granting of this patent in the U.S. and other essential pharmaceutical markets, we are fortifying narmafotinib’s patent portfolio, ensuring robust protection and maximizing the Company's intellectual property for long-term success." This assertion reflects Amplia’s commitment to advancing innovative therapies while prioritizing the safeguarding of their proprietary technology.
What is Narmafotinib?
Narmafotinib (AMP945) stands out as an advanced FAK inhibitor, specifically designed to target the protein Focal Adhesion Kinase (FAK). This protein is significantly over-expressed in pancreatic cancer, making it a prime target for interventions. As researchers delve deeper into its mechanisms, narmafotinib is drawing increasing attention in the realm of solid tumor therapies.
The noteworthy attributes of narmafotinib lie in its potency and selectivity. Early studies have demonstrated its favorable outcomes, and its clinical journey is now levelling up with the ongoing ACCENT trial. This trial investigates the drug in combination with established chemotherapies gemcitabine and Abraxane for first-line patients battling advanced pancreatic cancer.
Results from this trial are promising, with a reported confirmed response rate of 33%, significantly surpassing the 23% benchmark established in the MPACT study, which examined gemcitabine and Abraxane alone. Furthermore, it has achieved an interim median progression-free survival (PFS) of 7.6 months, underscoring the drug's potential efficacy.
Ongoing Research and Future Trials
The excitement surrounding narmafotinib extends further with the recent initiation of another trial - the AMPLICITY trial. In this innovative study, researchers are evaluating the combination of narmafotinib with FOLFIRINOX, another chemotherapy regimen, in advanced pancreatic cancer patients. The introduction of this combination therapy could potentially enhance treatment outcomes for patients facing challenges in managing their disease.
About Amplia’s Commitment
Amplia Therapeutics Limited is dedicated to transforming patient care through its innovative FAK inhibitors, particularly targeting cancer and fibrosis. The FAK protein continues to emerge as a critical focal point in cancer research, with Amplia's specialized efforts directed towards addressing fibrotic cancers, such as those affecting the pancreas and ovaries. Additionally, FAK’s implications extend to various chronic diseases like idiopathic pulmonary fibrosis (IPF), further emphasizing the importance of Amplia's research.
The company is committed to providing cutting-edge therapies and addressing unmet medical needs while ensuring the sustainability of its intellectual property landscape. With the patent grant and promising clinical trial results, Amplia is well-positioned to make a significant impact in the realms of cancer treatment and chronic disease management.
Frequently Asked Questions
What is the significance of Amplia's patent grant?
The patent grant protects narmafotinib, ensuring exclusive rights until at least 2040, which enhances Amplia's market position and intellectual property security.
What conditions does Narmafotinib target?
Narmafotinib primarily targets pancreatic cancer but is also being explored for its potential in fibrotic cancers and other major diseases linked to FAK.
What are the results of the ACCENT trial?
The ACCENT trial reported a confirmed response rate of 33%, which is notably higher than traditional treatments, showing narmafotinib's effectiveness.
What is the AMPLICITY trial?
The AMPLICITY trial evaluates the combination of narmafotinib with FOLFIRINOX in advanced pancreatic cancer patients, exploring new treatment options to improve outcomes.
How can I learn more about Amplia Therapeutics?
For more information, please visit Amplia’s official website or follow their updates on social media platforms to stay current with their developments.
